Christiansen v. Spectrum Pharmaceuticals, Inc., et al. United States District Court for the Southern District of New York Putative Class Period based on motion practice: may 12, 2022 – september 22, 2022 Attorneys: Jeffrey P. Campisi JCampisi@kaplanfox.com Documents: Amended Complaint Opinion & Order on Motion to Dismiss Notice of Pendency of Action on Behalf of Purchasers of Spectrum Pharmaceuticals, Inc. (SPPI) Common Stock and the Reopening of the Lead Plaintiff Process By order of the Court dated August 4, 2025 in the action captioned Christiansen v. Spectrum Pharmaceuticals, Inc., Thomas J. Riga and Francois J. Lebel, Case 1:22-cv-10292 (VEC) (S.D.N.Y.) (the “Action”), the Court has reopened the lead plaintiff appointment process. Members of the putative class may move the Court to serve as substitute lead plaintiff not later than Wednesday, September 24, 2025. Members of the putative class may view the operative complaint and the Court’s decision on the motion to dismiss here. Previously, the Court appointed Kaplan Fox & Kilsheimer LLP to serve as Lead Counsel. The Action has been pending since 2022, and after substantial discovery and motion practice, the Action currently alleges violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against Spectrum Pharmaceuticals, Inc., Thomas J. Riga and Francois J. Lebel on behalf of purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period May 12, 2022 through September 22, 2022 for allegedly making false or misleading statements about a drug manufactured by Spectrum Pharmaceuticals, Inc. Shares of Spectrum Pharmaceuticals, Inc. traded on Nasdaq under the symbol SPPI. In July 2023, Assertio Holdings, Inc. (Nasdaq: ASRT) closed its acquisition of Spectrum Pharmaceuticals, Inc. If you have any questions about this Notice, the Action, your rights, or your interests, please e-mail attorney Jeffrey P. Campisi (jcampisi@kaplanfox.com) or contact him by phone, regular mail, or fax, or click here. Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP850 Third Avenue, 14th FloorNew York, New York 10022Telephone: (212) 329-8571Fax: (212)-687-7714E-mail: jcampisi@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Kaplan Fox Files Class Action to Recover Losses for Investors in the Easterly ROCMuni High Income Municipal Bond Fund See the Case Inari Medical, Inc. See the Case Barclays iPath Series B S&P 500 VIX Short-Term Futures ETN See the Case Charles River Laboratories International, Inc. See the Case Digital Currency Group, Inc. See the Case Spectrum Pharmaceuticals, Inc. See the Case Co-Diagnostics, Inc. See the Case Vale SA See the Case Geron Corporation See the Case Hecla Mining Company See the Case Textron Inc. See the Case Ambac Financial Group Securities Litigation See the Case
